Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder

  title={Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder},
  author={Dina Popovic and Mar{\'i}a Reinares and Jos{\'e} Manuel Goikolea and Caterina Mar Bonn{\'i}n and Ana M Gonz{\'a}lez-Pinto and Eduard Vieta},
  journal={European Neuropsychopharmacology},

Figures and Tables from this paper

Polarity Index of Psychological Interventions in Maintenance Treatment of Bipolar Disorder

The polarity index (PI) provides a measure of how much depression-preventive or (hypo) mania- preventive an intervention is and may guide the choice of adjunctive psychotherapy in the context of individualized long-term treatment of BD.

Epidemiological studies of medication use and effectiveness in bipolar disorder

Findings indicate that efforts to reduce treatment delay should especially target patients who are naïve to moodstabilizers and antipsychotics or diagnosed with BD during a brief hospitalization, and that combination therapies including lithium, valproate and quetiapine or olanzapine were associated with the lowest risks of treatment failure.

An overview of pharmacotherapy for bipolar I disorder

There is dire need for new, more targeted treatments in BD I, with a critical view of the side effects, as randomized controlled trials do not represent ‘real world’ patients and research efforts must also focus on treating cognitive deficits, which adds to lower functional outcome.

Second Generation Antipsychotics Monotherapy as Maintenance Treatment for Bipolar Disorder: a Systematic Review of Long-Term Studies

Amongst all antipsychotics assessed only aripiprazole, olanzapine, lurasidone, risperidone and quetiapine have been found to be competent for their use in monotherapy, according to RCT.

Pharmacological Management of Bipolar Depression: Acute Treatment, Maintenance, and Prophylaxis

The pharmacological treatment of bipolar depression mostly consists of combinations of at least two drugs, including mood stabilizers (lithium and anticonvulsants), atypical antipsychotics, and antidepressants.

Treatment Implications of Predominant Polarity and the Polarity Index: A Comprehensive Review

This review supports the clinical relevance of predominant polarity as a course specifier for BD and finds support from naturalistic studies that bipolar patients with a predominantly depressive polarity are more likely to be treated with an antidepressive stabilization package.

Treatment of bipolar depression: making sensible decisions

The metric of the likelihood to be helped or harmed (LHH) is the ratio of NNH to NNT and can illustrate the tradeoffs inherent in selecting medications.

Predominant Polarity and Polarity Index of Maintenance Treatments for Bipolar Disorder: A Validation Study in a Large Naturalistic Sample in Italy

Future prospective studies are needed in order to determine whether the predominant polarity is indeed one clinical factor that might guide the clinician in choosing the right mood stabilizer for BD maintenance treatment.

Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice?

The available evidence indicates that bipolar disorder patients should be treated primarily with lithium, combined in some cases with antipsychotics especially in acute treatments, and sometimes, because of intolerance or inefficacy of lithium, with anticonvulsants.



Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder

All of the pharmacological agents assessed were effective in the prevention of any kind of mood episode; however, different efficacy profiles were found for prevention of manic and/or depressive relapses.

Mood state at study entry as predictor of the polarity of relapse in bipolar disorder

Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone

Patients taking olanzapine added to lithium orValproate experienced sustained symptomatic remission, but not syndromic remission, for longer than those receiving lithium or valproate monotherapy.

Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients.

Lithium appears to be superior in prophylactic efficacy to carbamazepine in bipolar patients not previously treated with mood stabilizers, and should reinforce efforts to put and maintain such patients on treatment with lithium.

Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.

Compared to placebo, olanzapine delays relapse into subsequent mood episodes in bipolar I disorder patients who responded to open-label acute treatment with olanZapine for a manic or mixed episode.

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder.

Lamotrigine and lithium were superior to placebo for the prevention of mood episodes in bipolar I patients, with lamot Rigine predominantly effective against depression and lithium predominantly effectiveagainst mania.

Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127).

In patients stabilized on quetiapine plus lithium or divalproex, continued treatment was associated with a significant risk reduction in the time to recurrence of any mood event compared with placebo and lithium ordivalproEx.

Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.

Over a 100-week treatment period, aripiprazole monotherapy was effective for relapse prevention in patients who were initially stabilized on aripIPrazole for 6 consecutive weeks, and it maintained a good safety and tolerability profile.